Allure Capital is a private family office based in Perth, Western Australia. The firm runs two strategies: active investments into a small number of healthcare-software and medical-device businesses each year, and a passive public-markets allocation managed for the long term. One principal. Own capital. Personal attention.
Clinical · software · devices
In one paragraph
Allure Capital was founded in 2011 by Nathan Buzza — a Perth medical-technology entrepreneur whose previous companies include CommtechWireless (founded 1992, exited 2008 in a trade sale to Amcom Software), Alcidion (led the December 2015 RTO; Executive Director of the listed entity 2016–17), and ResApp Health (Non-Executive Director 2017–20; acquired by Pfizer in September 2022, thirty months after his tenure ended). The firm operates as a single-principal family office. Active capital goes into healthcare-software, medical-device and clinical-technology businesses where the engineering risk has been retired and the next milestone is commercial. Passive capital sits in a long-term public-markets allocation. The portfolio is deliberately small. One or two new active investments a year.
Two strategies
Most family offices over-allocate to one or the other. Allure runs both, with capital sized so the active strategy never depends on the passive book staying liquid.
Direct investment · Allure mandate
AUD $100k to $1m cheques into one or two Australian businesses each year. Paying customers, regulatory pathway in hand, exit horizon inside 36 months.
Public markets · long-term allocation
A long-term, low-cost allocation across Australian and global equities, fixed income and listed property. Held in the family-office vehicle alongside the active book. No timing, no tactical trading — the role is to grow steadily while the active strategy does its work.
Right now
Held investment
Halo Medical Devices
Clinical-grade digital goniometer. A passive seed shareholding retained under the Allure mandate.
Passive book
Long-term allocation held
Diversified Australian and global index exposure. Rebalanced occasionally.
What we do
Three categories of engagement under the active strategy, plus the passive allocation. The rest of what comes across the desk gets a polite no. Allure Capital also wholly owns Illuminati Magic, a deep-technology business working in applied artificial intelligence, computer vision and miniaturised electronics. It is run entirely separately from the healthcare mandate.
01
AUD $100k to $1m cheques into clinical-decision-support, hospital-platform and patient-engagement businesses with paying customers and a clear path to ASX or strategic exit inside 36 months.
02
Pre-IPO and pre-commercial medical-device companies where regulatory clearance is in hand and the next milestone is distribution or trade sale — not fundamental engineering risk.
03
Non-Executive Director and Chair-of-the-Board mandates for portfolio companies. Capital without governance is how portfolios go sideways, so Allure takes a seat and does the work that comes with it.
04
A long-term, low-cost diversified portfolio across Australian and global equities, fixed income and listed property. Held in the family-office vehicle. No tactical trading; rebalanced occasionally.
Why healthcare
The active mandate is narrow because Nathan has spent his career in medical communications, clinical decision support, hospital platforms and medical devices. The pattern-recognition for what works — and what doesn't — comes from operating, not from a screen.
When the next milestone is commercial, not engineering, that's when Allure's capital is most useful. Everything else gets a polite no.
Read the approach15+
Years operating
Founded 2011, continuous since
2
ASX-listed boards served
ASX:ALC · ASX:RAP
2015
Alcidion ASX listing
RTO · ASX:ALC · Executive Director 2016–17
2
Strategies in balance
Active medtech · passive public markets
How few we back
1–2Active investments per year
The active mandate is sized to one or two new positions in a calendar year. Everything we see is filtered against the same seven criteria. About ninety-five percent of proposals don't go further than the first meeting.
That's not an aesthetic preference. It's how a single principal can answer his own correspondence and still do the work the founder actually needs in the moments that matter.
The seven criteria
Allure's active investment criteria have not changed since July 2016. They are short, blunt, and they explain about ninety-five percent of why most proposals don't go anywhere — and why the ones that do, go fast.
Read the criteria
